Doximity, Inc. (NYSE: DOCS) is a Healthcare company (Medical - Healthcare Information Services) with a market capitalization of $5.5B. The Maz Rating grades it against the other companies in its sector.
Doximity, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $31.11, Doximity, Inc. trades at 41.6x trailing earnings, 8.4x sales and 6.0x book value, with an EV/EBITDA of 24.2. Over the last twelve months it generated about $659M of revenue and $133M of net income. It runs a gross margin of 86.8%, an operating margin of 26.3% and a net margin of 21.1%. It shows return on equity of 14.8%, return on invested capital of 12.6% and a free cash flow yield of 5.4%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 6.37. Over the past 52 weeks the share price ranged from $17.15 to $51.85, with a beta of 1.29.
Doximity, Inc. does not currently pay a dividend.
24 Wall Street analyst ratings cover the stock: 1 Strong Buy, 8 Buy, 13 Hold and 2 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Doximity, Inc. provides a digital platform, hosted in the cloud, specifically designed for healthcare practitioners throughout the United States. This platform delivers a suite of specialized tools, empowering its members to connect with peers, streamline patient treatment, conduct remote consultations, access current medical information and research, and advance their professional careers. Its primary clientele consists of pharmaceutical companies and healthcare organizations. Established in 2010, the entity initially operated as 3MD Communications, Inc. before rebranding to Doximity, Inc. in June of that year. The company's corporate headquarters are situated in San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Doximity, Inc. (DOCS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 13.6% / 30% · Interest income / Revenue 3.86% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 13.6% / 33% · Receivables / Mkt Cap (36m) 3.16% / 49% · Interest income / Revenue 3.86% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 13.6% / 33.33% · Receivables / Mkt Cap (24m) 3.16% / 33.33% · Interest income / Revenue 3.86% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.05% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 64.7% / 33.33% · Receivables / Avg Assets (4Q) 14.5% / 33.33% · Interest income / Revenue 3.86% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 65.3% / 33.33% · (Cash+Recv) / Total Assets 80.5% / 33.33% · Interest income / Revenue 3.86% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Doximity, Inc. (DOCS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Doximity, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 3.86% of each dividend: Doximity, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q2 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.